Apo-Amisulpride

Quốc gia: New Zealand

Ngôn ngữ: Tiếng Anh

Nguồn: Medsafe (Medicines Safety Authority)

Thành phần hoạt chất:

Amisulpride 50mg;  

Sẵn có từ:

Apotex NZ Ltd

INN (Tên quốc tế):

Amisulpride 50 mg

Liều dùng:

50 mg

Dạng dược phẩm:

Tablet

Thành phần:

Active: Amisulpride 50mg   Excipient: Lactose monohydrate Magnesium stearate Methylcellulose Microcrystalline cellulose Sodium starch glycolate

Các đơn vị trong gói:

Blister pack, PVC/Al, 60 tablets

Lớp học:

Prescription

Loại thuốc theo toa:

Prescription

Sản xuất bởi:

Cosma SpA

Chỉ dẫn điều trị:

Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Tóm tắt sản phẩm:

Package - Contents - Shelf Life: Blister pack, PVC/Al - 60 tablets - 36 months from date of manufacture stored at or below 25°C protect from light and moisture - Blister pack, PVC/Al - 90 tablets - 36 months from date of manufacture stored at or below 25°C protect from light and moisture - Blister pack, PVC/Al - 100 tablets - 36 months from date of manufacture stored at or below 25°C protect from light and moisture

Ngày ủy quyền:

2012-10-30

Đặc tính sản phẩm

NEW ZEALAND DATA SHEET
APO-AMISULPRIDE
AMISULPRIDE 50MG, 100MG & 200MG TABLETS
AND 400MG FILM-COATED TABLETS
Please refer to Medsafe website (
www.medsafe.govt.nz
) for the most recent datasheet
Page 1 of 14
PRESENTATION
APO-AMISULPRIDE 50mg are white to off-white, 6.0mm, round, biconvex tablets, with break line
on one side.
APO-AMISULPRIDE 100mg are white to off-white, 8.0mm, round, flat tablets, with break line on
one side.
APO-AMISULPRIDE 200mg are white to off-white, 11.0mm, round, flat tablets, with break line on
one side.
APO-AMISULPRIDE 400mg are white to off-white, 18.0mm long and 8.0mm wide, capsule
shaped tablets, with break line on one side.
INDICATIONS
Apo-Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in
which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative
symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including
patients characterized by predominant negative symptoms.
DOSAGE AND ADMINISTRATION
For acute psychotic episodes, oral doses between 400mg/day and
800mg/day are
recommended. In individual cases, the daily dose may be increased up to 1200mg/day. Doses
above 1200mg/day have not been extensively evaluated for safety and therefore should not be
used. Doses above 800mg/day have not been shown to be superior to lower doses and may
increase the incidence of adverse events. No specific titration is required when initiating the
treatment with amisulpride. Doses should be adjusted according to individual response.
Doses should preferably be administered before meals.
Amisulpride should be administered b.i.d for doses above 400mg.
For patients with mixed positive and negative symptoms, doses should be adjusted to obtain
optimal control of positive symptoms.
Mainte